Anti-p53 Antibodies in Sera of Workers Occupationally Exposed to Vinyl Chloride

Trivers, Glennwood E.; Cawley, Helen L.; Debenedetti, V; Hollstein, Monica; Marion, Marie‐Jeanne; Bennett, William P.; Hoover, Marie L.; Prives, Carol; Tamburro, Carlo C.; Harris, Curtis C.

doi:10.1093/jnci/87.18.1400

Cited by 125 publications

(67 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antibodies to p53 protein have never been detected in the serum of healthy subjects (Rosenfeld et al, 1997). In some cases, anti-p53 antibodies were found in the serum of cancer patients before clinical manifestation of disease (Schlichtholz et al, 1994;Lubin et al, 1995;Trivers et al, 1995). Trivers and co-workers determined the presence of anti-p53 antibodies 4 months, in particular even 11.3 and 10.8 years, before diagnosis of cancer.…”

Section: Discussionmentioning

confidence: 99%

p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer

et al. 1999

View full text Add to dashboard Cite

The oncogene product epidermal growth factor receptor (EGF-R), the tumour suppressor gene product p53 and anti-p53 antibodies are detectable in the serum of certain cancer patients. Increased levels of some of these products were reported in lung cancer patients after occupational asbestos exposure and after exposure to polycyclic aromatic hydrocarbons or vinylchloride. In the first step, this study investigated the possible diagnostic value of serum EGF-R, p53-protein and anti-p53 antibodies, measured by an enzyme-linked immunosorbent assay, in lung tumour patients. In addition to being investigated on a molecular epidemiological basis, these parameters were examined as biomarkers of carcinogenesis, especially with regard to asbestos incorporation effects or of radon-induced lung cancers. Also, a possible effect of cigarette smoking and age dependence were studied. A total of 116 male patients with lung or pleural tumours were examined. The histological classification was four small-cell cancers, six large-cell cancers, 32 adenocarcinomas, 47 squamous carcinomas, 12 mixed lung carcinomas, five diffuse malignant mesotheliomas and ten lung metastasis of extrapulmonary tumours. Twenty-two lung cancers and all mesotheliomas were related to asbestos, 22 lung cancers were related to ionizing radiation and 61 patients had cigarette smoke-related lung cancer. Besides these patients 50 male patients with non-malignant lung or pleural diseases were included; of the latter eight subjects suffered from asbestosis. Controls were 129 male subjects without any lung disease. No significantly elevated or decreased serum values for p53 protein, EGF-R, or anti-p53 antibodies as a function of histological tumour type, age, or degree and type of exposure (asbestos, smoking, ionizing radiation) could be found. The utility of p53-protein, EGF-R and anti-p53 antibodies as routine biomarkers for screening occupationally derived lung cancers is limited. © 1999 Cancer Research Campaign

show abstract

Section: Discussionmentioning

confidence: 99%

p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer

et al. 1999

View full text Add to dashboard Cite

show abstract

“…These data showed that presence of antibodies against six of these antigens was a good diagnostic classifier for prostate cancer. Importantly, it has also been observed that antibody responses to p53 were diagnostic for asymptomatic liver tumours in individuals that were exposed to toxic compounds [76]. Strikingly, these antibody responses could even predate clinical diagnosis of oesophageal cancer [77].…”

Section: Early Detection Of Cancermentioning

confidence: 99%

Immunoproteomics: From biomarker discovery to diagnostic applications

Tjalsma

Schaeps

Swinkels

2008

Proteomics Clinical Apps

View full text Add to dashboard Cite

Circulating antibodies reflect a molecular imprint of antigens that are related to autoimmune diseases, cancer or infection. Importantly, serum antibodies are useful clinical markers as they carry diagnostic information from all around the human body. Moreover, the amplification cascade governed by the humoral immune system causes a surplus of circulating antibodies after appearance of the corresponding (low abundance) antigen. In combination with the fact that antibodies are highly stable compared to many other serum proteins, they seem ideal to be implemented in clinical diagnostic assays for the detection of antigen-associated diseases. This review summarises advances in immunoproteomics with respect to technologies for biomarker discovery, with special emphasis on recently developed gel-free MS-based approaches, and looks forward to potential immunoproteomic applications in diagnostic medicine.

show abstract

“…Anti-p53 serum antibodies have been associated with poor prognosis and advanced stage in breast (Schlichtholz et al, 1992;Angelopoulou et al, 1996), head and neck (Bourhis et al, 1996), colorectal (Houbiers et al, 1995;Coomber et al, 1996) and ovarian (Angelopoulou et al, 1996;Gadducci et al, 1996) cancers. However, serological assessment of anti-p53 antibodies seems also to allow detection of tumours at an early and therefore more treatable stage (Lubin et al, 1995b;Trivers et al, 1995Trivers et al, , 1996. Moreover, this non-invasive test is adapted to the follow-up of cancer patients in clinical routine laboratories.…”

mentioning

confidence: 99%

Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma

et al. 1999

View full text Add to dashboard Cite

Summary p53 alterations are considered to be predictive of poor prognosis in hepatocellular carcinoma (HCC) and may induce a humoral response. Anti-p53 serum antibodies were assessed by enzyme-linked immunosorbent assay (ELISA) using purified recombinant human p53 on 130 European HCC patients before treatment and during the clinical course of the disease. p53 immunohistochemistry was performed on tumours from the 52 patients who underwent surgery, and DNA sequencing analysis was initiated when circulating anti-p53 antibodies were detected. Nine (7%) HCC patients had anti-p53 serum antibodies before treatment. During a mean period of 30 months of follow-up, all the negative patients remained negative, even when recurrence was observed. Of the nine positive patients, eight were still positive 12-30 months after surgery. The presence of anti-p53 serum antibodies was correlated neither with mutation of the p53 gene nor the serum alphafetoprotein levels and clinicopathological characterics of the tumours. However, a greater incidence of vascular invasion and accumulation of p53 protein were observed in the tumours of these patients (P < 0.03 and P < 0.01 respectively) as well as a better survival rate without recurrence (P = 0.05). In conclusion, as was recently shown in pancreatic cancer, anti-p53 serum antibodies may constitute a marker of relative 'good prognosis' in a subgroup of patients exhibiting one or several markers traditionally thought to be of bad prognosis.

show abstract

Anti-p53 Antibodies in Sera of Workers Occupationally Exposed to Vinyl Chloride

Abstract: Serum anti-p53 antibodies can predate clinical diagnosis of certain tumors, such as ASL, and may be useful in identifying individuals at high cancer risk, such as workers with occupational exposure to vinyl chloride.

Cited by 125 publications

References 0 publications

p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer

p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer

Immunoproteomics: From biomarker discovery to diagnostic applications

Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma

Contact Info

Product

Resources

About